Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HYOU1 antisense RNA 1 (HYOU1-AS1)
- Target
- HYOU1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Natural antisense transcript (NAT)
01
Overview
HYOU1 antisense RNA 1 (HYOU1-AS1) is a long non-coding RNA transcribed antisense to the protein-coding gene Hypoxia Up-Regulated 1 (HYOU1). This lncRNA is highly expressed in triple-negative breast cancer (TNBC) cells and promotes tumor progression by boosting HYOU1 expression through competitive interaction with the RNA-binding protein hnRNPA1, thereby releasing post-transcriptional inhibition of HYOU1 mRNA. Knockdown of HYOU1-AS1 inhibits proliferation and migration of TNBC cells and reduces tumor formation in mice. Increased HYOU1-AS1 or HYOU1 levels are associated with poor prognosis in breast cancer, and the pathway may be considered a potential therapeutic target for future RNA-based treatments[1][3][7][8][9]. Key molecular features: - lncRNA - Antisense to HYOU1 - Regulates gene expression at the post-transcriptional level via protein (hnRNPA1) binding - Implicated in cancer biology (mainly breast cancer) - Target for RNA-based therapy research
- Other names
- HYOU1-AS1HYOU1-ASHYOU1 antisense RNA 1
02
Mechanism of action
Antisense oligonucleotide (ASO)-mediated inhibition or degradation of HYOU1-AS1 RNA to suppress its function Potential gene silencing, alteration of chromatin state, or interference with RNA-protein interactions
03
Biological functions
Regulation of gene expression (primarily cis-acting)Promotion of cell proliferation and migration (especially in breast cancer cells)Modulation of hypoxia response via the HYOU1 geneCompetitive binding to RNA-binding protein hnRNPA1, releasing inhibition of HYOU1 mRNA
04
Disease associations
Cancer (especially triple-negative breast cancer, TNBC)Likely involved in other tumors where HYOU1 upregulation is observedPotential roles in diseases associated with hypoxia and cellular stress (inferred from HYOU1 function)
05
Safety considerations
General ASO/lncRNA-targeting safety concerns: off-target effects, delivery to intended tissues/cells, and immune activationKnockdown of HYOU1-AS1 or HYOU1 in non-cancer cells could theoretically impair cellular protection against hypoxiaNovelty of lncRNA therapies means clinical safety profile is mostly unknown at this time
06
Interacting drugs
No directly approved drugs are known to interact with HYOU1-AS1 as of this date.
2 more in the full profile.
07
Biomarkers
HYOU1-AS1 expression may serve as a prognostic biomarker in triple-negative breast cancerHigh HYOU1-AS1 or HYOU1 levels correlate with poor breast cancer outcomesHYOU1 mRNA/protein level (as a downstream target)
Beyond the preview
Go deeper on HYOU1 antisense RNA 1 (HYOU1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYOU1 antisense RNA 1 (HYOU1-AS1).